RESEARCH WORKSPACE / CANADA

Move one drug project forward.

Keep the brief, evidence, questions and decisions connected—from first discussion to adviser handoff.

Research previewSingle-browser project · Not saved yet

Use public information and non-confidential working notes. Entries are not sent to Patefacta. Saving uses this browser profile; JSON lets you keep separate copies. This preview has no team accounts or synchronization.

Project overviewSection 1 of 6

01 / PROJECT OVERVIEW

A clear view of the work ahead.

Resolve questions, record the basis, and carry the same information into your next discussion.

Questions still open0Includes answers needing recheck
Actions ready to work0Dependencies recorded as done
References to check0Based on user-recorded status
Decisions to revisit0Linked project inputs changed

Next actions

Turn a question into an action

Add an owner, a target date and any dependencies. Your action list will appear here.

Project context

User entered
Asset
Not supplied
This project should answer
Define the decision or discussion you are preparing for.
Discussion purpose
Not selected
Target date
Not supplied
0 recorded items need recheck

Editing a profile or linked input can make a prior review stale. Earlier entries remain visible with their review state.

One project, connected work

Use Canadian source context

Find products in the approved catalogue snapshot, attach exact official record links, and keep limitations with the claim.

Prepare a useful handoff

Your current brief, references, unresolved questions, assumptions and decisions become one editable meeting draft.

Official guidance and scope of this research preview

These sources informed the workflow structure. They do not validate this project, determine its requirements or establish that any selected pathway is appropriate.

This is a browser-local research preview. Project entries and review flags are user supplied; they are not independently authenticated. Published drug evidence remains subject to the explorer's source coverage and matching limitations.

CHOOSE A WORKING FOCUS

Start with the work you need to move forward.

Choose a starting structure, then keep, change or remove its prompts. Different focuses can share the same evidence register.

Prepare a development discussion

Clarify the meeting objective, company position and evidence to discuss with an adviser.

Investigate a Canadian opportunity

Organize existing Canadian product context, asset assumptions and questions for qualified review.

Explore price and quantity assumptions

Keep price fields, packaging, phases and alternative assumptions consistent before comparing totals.

RESEARCH PILOT

Canadian review brief

Follow a submission and a reimbursement project side by side, then carry the sources and open questions into a client brief.

Datopotamab deruxtecan · oncology example

Dated example, reviewed on

  • Health Canada · submission under review

    Health Canada lists an AstraZeneca Canada datopotamab deruxtecan submission accepted in February 2026 for aligned review. The public row gives an oncology drug class and leaves the exact indication unspecified.

    Source date

    Open official source ↗
  • Health Canada · earlier sponsor cancellation

    Health Canada records a sponsor cancellation on March 21, 2025 for an earlier datopotamab deruxtecan submission, control number 284807.

    Source date

    Open official source ↗
  • Canada’s Drug Agency · reimbursement review

    CDA-AMC lists project PC0464-000 for a specified triple-negative breast cancer population, with pre-NOC status at filing. The schedule shown targets December 24, 2026 for public draft feedback to open and January 15, 2027 for it to close.

    Source date

    Open official source ↗
Exact indication match unconfirmed

The ingredient and sponsor match. The public Health Canada row leaves the indication unspecified, and the earlier cancellation belongs to a separate filing.

Adds three references, one question and one follow-up action. Dates are from the cited pages and can change. Reopen the source pages before using the brief.

PATEFACTA — PROJECT PREPARATION DRAFT

Untitled project
User-entered project information. No professional approval or source completeness is implied.

PRODUCT AND PROJECT BRIEF
name: Not supplied
asset: Not supplied
ingredient: Not supplied
indication: Not supplied
population: Not supplied
form: Not supplied
route: Not supplied
objective: Not supplied
stage: unspecified
meetingPurpose: unspecified
targetDate: Not supplied

EVIDENCE REGISTER
No evidence recorded. This does not establish that evidence is absent or unnecessary.

QUESTIONS, COMPANY POSITIONS AND ANSWERS
No questions recorded.

ACTIONS AND DEPENDENCIES
No actions recorded.

PUBLIC-PRICE / USER-ASSUMPTION SCENARIOS — 30 DAYS, CAD
No scenarios recorded.

USER DECISION RECORD
No decisions recorded.

EXTERNAL GUIDANCE REFERENCES
PW-HC-MEETING: Health Canada pre-application and filing guidance
https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/management-drug-submissions-applications/pre-application-filing.html
Official meeting-purpose, product-information, question and preparation guidance. The appropriate meeting and scientific acceptability require professional review.
PW-HC-SBD: Summary Basis of Decision coverage
https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/summary-basis-decision.html
Historical authorization considerations for selected drugs; this is not universal coverage.
PW-HC-HISTORY: Summary Basis of Decision frequently asked questions
https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/summary-basis-decision/frequently-asked-questions-summary-basis-decision-project-phase-2.html
A historical decision summary is not up-to-date product information.
PW-ON-PRICE: Ontario Formulary
https://www.formulary.health.gov.on.ca/formulary/
Public drug price and Amount MOH Pays are separate fields. Public prices do not disclose confidential negotiated net prices.

SCOPE AND LIMITATIONS
Working preparation draft. User-entered facts, answers and review flags are unauthenticated; they do not establish professional approval.
This is one local project. No team account, synchronization, notifications, confidential-document service or automatic source refresh is provided.
Historical Canadian examples do not establish the pathway, studies, eligibility or evidence requirements for a new asset. Meeting purpose and materials need appropriate expert review.
Scenario totals are CAD arithmetic under explicit user assumptions. They do not establish therapeutic equivalence, clinical dosing, net prices, reimbursement, cost-effectiveness or a complete budget-impact analysis.
Quantity phases and copied alternatives are user-created planning assumptions. Phase days must cover the full shared period; no dose, titration schedule or purchase-pack rounding is suggested.